CSE: PHRMOTCQB: PHRRF
Contact us
Menu

Newsroom

Press releases and media contact.

Press releases

Get news alerts →
October 17, 2025
Pipeline
PharmaTher Applauds FDA’s Commissioner’s National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
October 16, 2025
Pipeline
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson’s Disease
October 15, 2025
Platform & partnering
PharmaTher Announces KetAImine™ — AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
October 8, 2025
Pipeline
PharmaTher Provides Update on Ketamine Program for LID-Parkinson’s Disease
October 2, 2025
Pipeline
PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy
October 1, 2025
Pipeline
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
August 27, 2025
Pipeline
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine, Aligned with FDA’s CNPV National Priority Initiative
August 26, 2025
Pipeline
PharmaTher Provides Corporate Update Following FDA Approval of Ketamine
August 14, 2025
Financial
PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine
August 11, 2025
Pipeline
PharmaTher Announces FDA Approval of Ketamine
July 2, 2025
Financial
PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine
June 24, 2025
Pipeline
PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market
June 18, 2025
Pipeline
PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications
May 16, 2025
Pipeline
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025
May 14, 2025
Pipeline
PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization
March 11, 2025
Pipeline
PharmaTher Receives US FDA Approval Goal Date for Ketamine
March 3, 2025
Pipeline
PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine
February 12, 2025
Pipeline
PharmaTher Provides Update on FDA New Drug Application for Ketamine
January 6, 2025
Financial
PharmaTher CEO Issues Letter to Shareholders
November 26, 2024
Pipeline
PharmaTher Announces Update on FDA New Drug Application for Ketamine

All PharmaTher press releases since October 2020, newest first.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.